Introduction
Ask most people what's in a psilocybin mushroom, and they'll say "psilocybin." Ask a pharmacologist the same question, and they'll usually correct you: the mushroom contains psilocybin, but the compound doing the actual pharmacological work in the body is psilocin. These two molecules get used interchangeably in casual writing, and even in some clinical and popular-science coverage, which creates confusion that matters more than it might seem.
Psilocybin and psilocin are chemically distinct compounds with different structures, different stability profiles, different pharmacokinetics, and, critically, different practical implications for anyone trying to understand how the mushroom compound actually works. This article lays out the differences precisely, building on the foundational overview in What Is Psilocybin? and setting up the more technical pharmacology, metabolism, and stability articles later in this series.
As with the rest of this series, nothing here constitutes dosing, sourcing, or usage guidance. This is a chemistry and pharmacology explainer.
The Short Answer
Psilocybin is the compound naturally produced and stored by Psilocybe mushrooms. It is a prodrug, chemically stable, water-soluble, and pharmacologically inert until the body metabolizes it. Psilocin is the active metabolite the body produces from psilocybin through rapid enzymatic dephosphorylation. Psilocin is the molecule that actually binds serotonin receptors and produces psychoactive effects. Structurally, the two differ by a single phosphate group, but that one group changes almost everything about how the compound behaves, both in nature and in the body.
Chemical Structure: One Phosphate Group, Two Very Different Molecules
Both molecules share the same tryptamine backbone: an indole ring system with a dimethylated ethylamine side chain. The difference is at the 4-position of the indole ring.
- Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine, C₁₂H₁₇N₂O₄P) carries a phosphate ester group at that position.
- Psilocin (4-hydroxy-N,N-dimethyltryptamine, IUPAC name 3-(2-(dimethylamino)ethyl)-1H-indol-4-ol, C₁₂H₁₆N₂O) has a free hydroxyl group in the same position instead.
That single structural difference, a phosphate ester versus a free hydroxyl, is what separates a shelf-stable prodrug from a comparatively fragile active compound. Phosphate esters are, in general pharmaceutical chemistry, a well-established strategy precisely because they tend to be more water-soluble and chemically robust than the free hydroxyl-bearing parent compound, which is exactly the pattern seen here.
Why the Body Converts One Into the Other
The phosphate group on psilocybin isn't decorative, it's a metabolic switch. Once ingested, that phosphate ester is rapidly cleaved by alkaline phosphatase enzymes and non-specific esterases, primarily in the intestinal wall and liver, converting psilocybin into psilocin within minutes of absorption. This is why psilocybin itself is difficult to detect in blood plasma for any meaningful length of time after ingestion, while psilocin appears quickly and remains measurable for hours.
The reverse does not happen, psilocin is not converted back into psilocybin in the body. The relationship is strictly one-directional: psilocybin (prodrug) → psilocin (active metabolite) → further downstream metabolites, discussed below.
Psilocin doesn't simply sit in the bloodstream unchanged, either. It undergoes further metabolism through at least two separate pathways. A large portion is glucuronidated (attached to a glucuronic acid molecule) to form psilocin-O-glucuronide, a water-soluble conjugate that is subsequently excreted. Separately, some psilocin undergoes demethylation and oxidative deamination, a process believed to be catalyzed by monoamine oxidase, to form an intermediate metabolite, 4-hydroxyindole-3-acetaldehyde, which is then further processed into either 4-hydroxytryptophol or 4-hydroxyindole-3-acetic acid. Roughly a third of a given psilocybin dose is ultimately excreted in urine as 4-hydroxyindole-3-acetic acid, alongside psilocin-O-glucuronide as the other major urinary metabolite. This full metabolic cascade, and what it means for detection windows and pharmacokinetic modeling, is covered in detail in the dedicated Psilocybin Metabolism article later in this series.
Pharmacological Activity: Why Psilocin Is "The Active One"
Psilocybin itself has negligible direct activity at serotonin receptors, its job, chemically speaking, is to survive digestion and absorption intact and then get out of the way. Psilocin is the molecule that actually engages the central nervous system, acting primarily as a partial agonist at serotonin 5-HT2A receptors, with secondary activity at 5-HT1A and 5-HT2C receptor subtypes. This receptor interaction, concentrated in cortical regions like the prefrontal cortex, is the mechanistic basis for essentially every acute perceptual and mood-related effect associated with psilocybin-containing mushrooms.
This is worth stating plainly because of how often it gets glossed over in casual writing: psilocybin is not psychoactive in any meaningful direct sense. When researchers study "psilocybin's effects on the brain," what they are functionally studying, at the receptor level, is psilocin's effects. Psilocybin's contribution is upstream and logistical, it determines how much psilocin becomes available, how quickly, and via what route, but it does not itself drive the receptor pharmacology.
This upstream/downstream framing also explains why formulation strategy matters so much in current drug development. If a research group wants to control the onset, intensity, or duration of psilocin's effects, they have two structurally different levers available. One is to modify psilocybin's own pharmacokinetics, for example, through alternative routes of administration that change how quickly the phosphate group is cleaved and how much psilocin reaches systemic circulation at once. The other is to bypass psilocybin's role in the process altogether, by administering a synthetic prodrug or formulation designed to deliver psilocin directly, or via a different conversion chemistry, rather than relying on the body's own alkaline phosphatase activity. Both strategies are active areas of pharmaceutical research, precisely because they offer different ways of solving the same underlying clinical problem: psilocybin's natural pharmacokinetics, inherited from its role as a fungal storage molecule rather than as an engineered drug, are not necessarily optimal for a therapeutic protocol that benefits from predictable timing and duration.
Stability: The Practical Reason the Distinction Matters
This is where the difference between the two molecules becomes more than academic. Psilocin is chemically unstable in ways that psilocybin is not, and this has real consequences for anyone working with either compound analytically or pharmaceutically.
Psilocin's free hydroxyl group and the indole ring's electron-rich structure make it prone to oxidation on exposure to air, light, and certain pH conditions. This oxidative instability is well documented in the medicinal chemistry literature: researchers developing psilocin-based drug candidates have explicitly identified chemical stability during storage and handling as the primary challenge for psilocin salts, as distinct from psilocybin, precisely because unmodified psilocin degrades far more readily.
It's also the chemical explanation behind a phenomenon long observed by mycologists: the blue bruising reaction seen when Psilocybe mushroom tissue is cut, handled, or damaged. That blue-green discoloration is widely attributed to oxidation reactions involving psilocin and related compounds in the fungal tissue, a visible, macroscopic signal of exactly the same chemical fragility that makes psilocin difficult to formulate into a stable pharmaceutical product. Psilocybin, protected by its phosphate group, does not trigger this reaction in the same way.
This stability gap has become enough of a practical bottleneck that it's now an active area of pharmaceutical research in its own right. A 2025 medicinal chemistry study out of Uppsala University synthesized and evaluated a library of fifteen psilocin ester prodrugs and six psilocin salts specifically as potential alternatives to psilocybin, aiming to find forms that offered predictable pharmacokinetics and reduced the risk of the intact prodrug itself producing unwanted pharmacological effects while circulating in the body. The same research distinguished two separate engineering problems: for psilocin ester prodrugs, ensuring rapid and complete hydrolysis back to psilocin is critical, since incomplete conversion risks leaving pharmacologically active prodrug in circulation; for psilocin salts, the central challenge is improving chemical stability enough to survive ordinary storage and handling. Separately, patent filings in this space describe specific psilocin salt forms, including psilocin benzoate and psilocin succinate, developed specifically for improved shelf-life stability and resistance to oxidative degradation, with one disclosure noting stability of only about three weeks for some formulations, which underscores just how significant the underlying instability problem is. This entire subject, why psilocin degrades, what accelerates it, and how it's mitigated, is explored in full in the Psilocybin Stability and Factors Affecting Psilocybin Degradation articles later in this series.
The cost side of this problem is worth flagging too, because it shapes which approach ends up dominating pharmaceutical development pipelines. Current medical-grade psilocybin production relies on a complicated, multistep phosphorylation synthesis that is comparatively expensive and inefficient at scale. Psilocin ester prodrugs and salts, by contrast, can in principle be produced more cheaply, salt formation, for instance, can be as simple as adding an appropriate acid and evaporating the solution, compared with the more complex and moderately-yielding phosphorylation chemistry required to produce psilocybin itself. That cost advantage is precisely why instability is such an active research problem rather than a reason to abandon psilocin-based approaches altogether: if the stability challenge can be solved, psilocin derivatives could offer a cheaper, more scalable route to a therapeutic product than manufacturing psilocybin directly.
A Note on How the Literature Sometimes Blurs the Two
Part of why the psilocybin/psilocin distinction is worth spelling out carefully is that even serious sources don't always keep it perfectly clean. Clinical pharmacology papers will often report "psilocybin's pharmacokinetics" when what was actually measured in blood plasma was psilocin, since psilocybin itself clears too quickly to be a practically useful marker in most assays. This isn't sloppiness so much as a shorthand that's understood within the field, but it can be genuinely confusing to a general reader trying to piece together which molecule is responsible for which effect.
A similar blurring happens in popular coverage of mushroom potency. When an article states that a given Psilocybe species or strain is "high in psilocybin," it is typically referring to total measured tryptamine alkaloid content, psilocybin plus psilocin plus related minor compounds such as baeocystin, rather than psilocybin in isolation. Since the relative proportion of psilocybin to psilocin in dried or stored tissue can shift over time as psilocybin degrades or converts, a potency figure measured at one point in a sample's shelf life is not necessarily representative of the same sample months later. This has direct relevance for the analytical testing methods discussed later in this series, where distinguishing and separately quantifying psilocybin and psilocin, rather than reporting a combined figure, is treated as a baseline requirement for any rigorous chromatographic method.
Side-by-Side Comparison
Property
Psilocybin
Psilocin
Role
Prodrug
Active metabolite
IUPAC-type name
4-phosphoryloxy-N,N-dimethyltryptamine
4-hydroxy-N,N-dimethyltryptamine
Molecular formula
C₁₂H₁₇N₂O₄P
C₁₂H₁₆N₂O
Key functional group
Phosphate ester at 4-position
Free hydroxyl at 4-position
Water solubility
High
Comparatively lower
Chemical stability
Relatively stable
Prone to oxidative degradation
Direct receptor activity
Negligible
Partial agonist at 5-HT2A (primary), plus 5-HT1A/5-HT2C
Presence in fresh mushroom tissue
Primary stored form
Present in smaller amounts; increases as psilocybin degrades
Detectability in plasma after ingestion
Brief, low concentration
Rapid appearance, measurable for hours
Associated with mushroom "blue bruising"
No
Yes (via oxidation)
Detection and Measurement: Why the Distinction Matters Analytically
The psilocybin/psilocin distinction isn't just a matter of pharmacological semantics, it has direct, practical consequences for anyone doing analytical chemistry on mushroom material or biological samples. Because psilocybin converts to psilocin so rapidly in the body, a blood or urine sample taken even a short time after ingestion may show little or no detectable psilocybin at all, with psilocin and its downstream metabolites (particularly psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid) making up the bulk of what's measurable. An analytical method validated only against psilocybin, without accounting for these downstream compounds, risks badly underestimating exposure.
The same principle applies in reverse when analyzing dried fungal material rather than biological samples. Because psilocybin degrades over time, accelerated by heat, light, moisture, and pH, as covered in the Psilocybin Stability article, a chromatographic analysis of older or improperly stored mushroom tissue may show a mix of psilocybin and psilocin rather than psilocybin alone, even if psilocin was present only in trace amounts at the time of harvest. Any analytical method that fails to separate and independently quantify the two compounds, rather than reporting a single combined "psilocybin content" figure, is at risk of misrepresenting both the original composition of the material and how much of that composition has degraded. This distinction is treated in more technical depth in the Analytical Testing of Psilocybin Materials article later in this series.
Why Mushrooms Store Psilocybin Rather Than Psilocin
From a biochemical standpoint, it makes sense that the fungus stores the phosphorylated, more stable form rather than the reactive free-hydroxyl form. Fungal tissue, like any biological system, benefits from storing bioactive or potentially reactive compounds in a chemically protected form until they're needed or released, the same general logic that underlies prodrug design in pharmaceutical chemistry. Storing psilocin directly, in its free and reactive form, would leave the compound vulnerable to oxidative breakdown inside the organism's own tissue long before it could serve whatever biological function it evolved to serve, whatever that function ultimately turns out to be, since the ecological role of psilocybin production in fungi (commonly hypothesized to relate to deterring insect predation or competing microorganisms) remains an area of ongoing study rather than settled fact. This is discussed further, alongside the broader ecological and evolutionary questions around why these fungi produce tryptamine alkaloids at all, in the Psilocybe cubensis: Taxonomy and Characteristics article later in this series.
Frequently Asked Questions
Is psilocybin the same as psilocin? No. Psilocybin is the compound found in the mushroom itself; psilocin is the active metabolite the body produces after enzymes remove psilocybin's phosphate group. They are structurally related but chemically and pharmacologically distinct.
Which one is psychoactive, psilocybin or psilocin? Psilocin is the molecule that binds serotonin receptors and produces psychoactive effects. Psilocybin itself has negligible direct activity; it functions as a stable delivery form that the body converts into psilocin.
Why is psilocin less stable than psilocybin? Psilocin has a free hydroxyl group on its indole ring, making it chemically reactive and prone to oxidation when exposed to air, light, or certain pH conditions. Psilocybin's phosphate group protects the molecule from this same degradation pathway.
Does fresh mushroom tissue contain psilocin? Fresh tissue primarily stores psilocybin. Psilocin is present in smaller amounts and its relative concentration tends to increase as psilocybin degrades or is converted post-harvest.
What causes the blue discoloration when a mushroom is cut or bruised? The blue-green bruising commonly seen in Psilocybe species is widely attributed to oxidation reactions involving psilocin and related compounds released or exposed when fungal tissue is damaged.
Can psilocin convert back into psilocybin? No. The metabolic conversion is one-directional. Psilocybin is dephosphorylated into psilocin, and psilocin is then further metabolized into other downstream compounds, it is not converted back into psilocybin.
Key Takeaways
- Psilocybin and psilocin differ by a single functional group, a phosphate ester versus a free hydroxyl, but that difference changes their solubility, stability, and pharmacological activity entirely.
- Psilocybin is a stable, water-soluble prodrug with negligible direct receptor activity; psilocin is the active metabolite responsible for psychoactive effects via partial agonism at 5-HT2A receptors.
- The body converts psilocybin to psilocin rapidly and irreversibly through enzymatic dephosphorylation.
- Psilocin's chemical instability, its tendency to oxidize, is a significant practical challenge in pharmaceutical formulation and is the likely explanation for the blue bruising reaction seen in damaged mushroom tissue.
- Current medicinal chemistry research is actively developing psilocin salts and ester prodrugs specifically to work around psilocin's inherent instability.
This article is for scientific and educational purposes only. It does not provide guidance on acquisition, dosing, or use of psilocybin or psilocin, and is not a substitute for professional medical or legal advice.